SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000891293-20-000051
Filing Date
2020-08-07
Accepted
2020-08-06 18:26:01
Documents
41
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cti10q06302020.htm   iXBRL 10-Q 1193797
2 EXHIBIT 3.1 ex31certificateofamend.htm EX-3.1 8196
3 EXHIBIT 31.1 ex311-ceo302q2fy20.htm EX-31.1 11045
4 EXHIBIT 31.2 ex312-cfo302q2fy20.htm EX-31.2 12139
5 EXHIBIT 32 ex32-ceocfo906q2fy20.htm EX-32 11934
  Complete submission text file 0000891293-20-000051.txt   3817985

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20200630.xsd EX-101.SCH 21321
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctic-20200630_cal.xml EX-101.CAL 57495
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctic-20200630_def.xml EX-101.DEF 109930
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20200630_lab.xml EX-101.LAB 343052
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20200630_pre.xml EX-101.PRE 191061
11 EXTRACTED XBRL INSTANCE DOCUMENT cti10q06302020_htm.xml XML 360462
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-28386 | Film No.: 201083207
SIC: 2834 Pharmaceutical Preparations